Walleye Trading’s ALX Oncology ALXO Stock Holding History

Walleye Trading’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-23,032	Closed	-$343K	–	4698
2023 Q4	$343K	Buy	+23,032	New	+$219K	﹤0.01%	3395

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Walleye Trading's ALXO Position: Q1 2024 in Review

Walleye Trading sold out of ALX Oncology (ALXO) in Q1 2024, closing a stake of 23,032 shares — an estimated $343K sold.

Walleye Trading first reported a position in ALXO in Q4 2023 and held it in 1 quarter. The position peaked at $343K in Q4 2023. 106 funds tracked by Wall St. Rank hold ALXO as of Q1 2024.

Walleye Trading reported no remaining ALX Oncology position as of Q1 2024 after selling out during the quarter.
Walleye Trading sold 23,032 ALX Oncology shares in Q1 2024, an estimated $343K.
Walleye Trading first reported a position in ALX Oncology in Q4 2023 and held it in 1 quarter.
Walleye Trading's ALX Oncology position peaked at $343K in Q4 2023.
106 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2024.

Based on Walleye Trading's 13F filing for Q1 2024, filed 15 May 2024.